The short version of FSFI endpoint fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-06-28. Anything still debated is marked as such rather than presented as settled.
Clinical programmes in this area have relied mainly on randomised, double-blind, placebo-controlled designs in premenopausal women. Primary endpoints usually combine a validated questionnaire covering desire domains with counts of satisfying sexual events and a separate measure of distress. Reported outcomes show statistically significant but modest average improvement over placebo, with wide individual variation. Adverse events such as nausea, flushing, and headache occur frequently and can limit tolerability. Whether short-term trial gains translate into lasting change for most users is an open question.
Evidence outside the studied population is sparse. Trials have concentrated on premenopausal women with a defined diagnosis, and data for postmenopausal women, men, and people taking interacting medications remain limited. Non-prescription use of the peptide for comparable goals is widespread but is not supported by published controlled data. Observed changes in blood pressure have drawn attention to cardiovascular monitoring during use. The literature generally frames the compound as a targeted receptor agonist rather than a general libido enhancer, and basic questions about mechanism and long-term safety are unresolved.
The melanocortin system comprises five G protein-coupled receptors, designated MC1 through MC5, that signal mainly through cyclic AMP accumulation. MC1R and MC2R are associated with pigmentation and adrenal steroid production, while MC3R and MC4R are expressed in the central nervous system and influence energy balance and behavior. MC5R appears in exocrine tissues. Natural agonists include alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone, and endogenous antagonists such as agouti-related protein modulate the same sites. This receptor family provides the framework within which bremelanotide activity is described.
Bremelanotide acts as an agonist at several melanocortin receptors, with the strongest reported activity at MC4R and measurable activity at MC1R and MC3R. Because MC4R is expressed in hypothalamic and limbic circuits, the proposed mechanism links receptor activation to modulation of central pathways involved in desire rather than to direct effects on peripheral genital tissue. The precise downstream steps remain incompletely characterized, and evidence for the involvement of specific neurotransmitters is suggestive rather than settled. Nausea and blood pressure elevation reported during trials are consistent with melanocortin signaling outside the intended target circuit.
Compared with melanotan II, bremelanotide is a smaller cyclic peptide with a more constrained backbone, which affects receptor selectivity and metabolic stability. Published descriptions give a plasma half-life on the order of a few hours after subcutaneous administration, with elimination through hepatic and renal routes and limited plasma protein binding. Central access is inferred from effects observed in animal models, although direct measurement in humans is limited. Handling and storage requirements follow from the peptide backbone, which is susceptible to hydrolysis and oxidation.
| Property | Value | Notes |
|---|---|---|
| Primary receptor target | MC4 melanocortin receptor | Other melanocortin subtypes are also activated |
| Typical route in approved use | Subcutaneous injection | Single-use format in the marketed product |
| Elimination half-life | Roughly two to three hours | Short exposure supports as-needed use |
| Common adverse events | Nausea, flushing, headache | Generally transient but can be dose limiting |
| Main studied group | Premenopausal women with low desire | Controlled data outside this group are limited |
Melanocortin receptors form a family of five G-protein-coupled receptors designated MC1 through MC5. Bremelanotide binds most strongly at MC4R and MC1R, with weaker activity reported at MC3R and MC5R. MC4R is expressed in hypothalamic nuclei that coordinate energy balance and aspects of sexual behaviour. The prevailing interpretation is that central MC4R activation, rather than peripheral vascular effects alone, drives the reported changes in desire. This account remains partly inferential, since direct receptor-level measurement in living humans is not practical.
After subcutaneous administration, plasma concentrations rise within roughly thirty minutes and the elimination half-life is short, on the order of two to three hours. Reported physiological responses include transient increases in blood pressure and nausea, which tended to diminish with repeated dosing in trial settings. Because the peptide clears quickly, effects are not expected to persist long after a dose. Absorption from non-injected routes is poorly characterised, and nasal delivery produced variable plasma levels in older work.
Clinical research typically uses randomised, double-blind, placebo-controlled designs. The most common primary endpoint is the desire domain score of the Female Sexual Function Index, sometimes paired with a distress measure. Secondary outcomes include arousal, satisfaction, and event-based counts of satisfying sexual episodes. Across trials, average improvements are modest and individual responses vary widely. Whether benefits persist beyond a few months, and whether they depend on baseline hormone status, remain open questions rather than settled findings.
Lyophilised peptide is generally held below minus twenty degrees Celsius, protected from light and moisture, because hydrolysis and oxidation accumulate faster at ambient temperature. Once reconstituted, solutions are typically kept between two and eight degrees Celsius and used within a short window defined by the supplier. Repeated freeze-thaw cycles are avoided since they promote aggregation and loss of soluble material. Container material matters as well, because peptides adsorb to certain plastics and glass surfaces at low concentration. Stability figures supplied by a vendor apply only to the specific lot and buffer that were tested.
Identity and purity are usually established with reversed-phase high-performance liquid chromatography combined with mass spectrometry. A gradient of water and acetonitrile containing trifluoroacetic acid is a common mobile phase, and ultraviolet detection near 214 nanometres responds to the peptide backbone. Mass spectrometry confirms the expected molecular mass and helps reveal truncation or oxidation products. Purity is reported as a peak-area percentage, a figure that depends on the wavelength and gradient used, so values from different laboratories are not always directly comparable. Peptide mapping and amino acid analysis provide additional confirmation when required.
== History == Glycogen was discovered by Claude Bernard. His experiments showed that the liver contained a substance that could give rise to reducing sugar by the action of a "ferment" in the liver. By 1857, he described the isolation of a substance he called "la matière glycogène", or "sugar-forming substance". Soon after the discovery of glycogen in the liver, M.A. Sanson found that muscular tissue also contains glycogen. The empirical formula for glycogen of (C6H10O5)n was established by August Kekulé in 1858. Sanson, M. A. "Note sur la formation physiologique du sucre dans l’economie animale." Comptes rendus des séances de l'Académie des Sciences 44 (1857): 1323–5.
=== Autoimmune diseases === Problems posed by the differences in the human and rodent immune systems have been overcome using a few strategies, so as to enable researchers to study autoimmune disorders using humanized models. As a result, the use of humanized mouse models has extended to various areas of immunology and disease research. For instance, humanized mice have been utilized to study human-tropic pathogens, liver cancer models, and the comparison of mouse models to human diseases NSG mice engrafted with PBMCs and administered with myelin antigens in Freund's adjuvant, and antigen-pulsed autologous dendritic cells have been used to study multiple sclerosis. Similarly, NSG mice engrafted with hematopoietic stem cells and administered with pristane have been used for studying lupus erythematosus. Furthermore, NOG mice engrafted with PBMCs has been used to study mechanisms of allografts rejection in vivo. The development of humanized mouse models has significantly advanced the study of autoimmune disorders and various areas of immunology and disease research. These models have provided a platform for investigating human diseases, immune responses, and therapeutic interventions, bridging the gap between human and rodent immune systems and offering valuable insights into disease pathogenesis and potential therapeutic strategies.
=== Taste === Salts can elicit all five basic tastes, e.g., salty (sodium chloride), sweet (lead diacetate, which will cause lead poisoning if ingested), sour (potassium bitartrate), bitter (magnesium sulfate), and umami or savory (monosodium glutamate).
Sources: en.wikipedia.org
=== Notable individuals === Some notable individuals have commented publicly on their experiences with LSD. Some of these comments date from the era when it was legally available in the US and Europe for non-medical uses. Others pertain to psychiatric treatment in the 1950s and 1960s. Still others describe experiences with illegal LSD, obtained for philosophic, artistic, therapeutic, spiritual, or recreational purposes.
2-Chloro-4,6-dimethoxy-1,3,5-triazine (CDMT) is a triazine derivative commonly used in acylation reactions for the synthesis of amides and esters as well as for activation of alcohols in a diverse range of other reactions. Almost exclusively used with N-methylmorpholine (NMM) as a Brønsted base, its reactivity is closely related to DMTMM.
Also, cats, which are generally regarded as obligate carnivores, occasionally eat grass to regurgitate indigestible material (such as hairballs), aid with hemoglobin production, and as a laxative. Many mammals, in the absence of sufficient food requirements in an environment, suppress their metabolism and conserve energy in a process known as hibernation. In the period preceding hibernation, larger mammals, such as bears, become polyphagic to increase fat stores, whereas smaller mammals prefer to collect and stash food. The slowing of the metabolism is accompanied by a decreased heart and respiratory rate, as well as a drop in internal temperatures, which can be around ambient temperature in some cases. For example, the internal temperatures of hibernating Arctic ground squirrels can drop to −2.9 °C (26.8 °F); however, the head and neck always stay above 0 °C (32 °F). A few mammals in hot environments aestivate in times of drought or extreme heat, for example the fat-tailed dwarf lemur (Cheirogaleus medius).
Sources: en.wikipedia.org
== Early life == Baldwin was born on February 27, 1962, in Winnetka, Illinois, and studied at New Trier Township High School in east Winnetka. Raised in the Chicago area, Baldwin played hockey as a youth.
Iranian vice president and reformist politician Mohammad Reza Aref, who is also an alumnus of the university, described the alleged use of a bunker-buster bomb as a "symbol of Trump's madness and ignorance".
Platt, Harris & Tishkoff (2026) reconstruct likely patterns of interbreeding between Neanderthals and anatomically modern humans on the basis of the study of their X chromosomes, interpreted as indicating that their interbreeding predominantly involved Neanderthal men mating with anatomically modern women. Evidence from the study of Middle and Upper Paleolithic assemblages, indicating that overall anatomically modern human occupations can be distinguished from Neanderthal ones on the basis of tighter and more cohesive clusters of archaeological remains, is presented by Merino-Pelaz & Cobo-Sánchez (2026). Evidence of utility of the study of nonmetric traits at the enamel-dentine junction for distinguishing teeth of Neanderthals and modern humans is presented by Becam, Chevalier & Colard (2026). Kanis et al. (2026) identify amino acid changes in the growth hormone receptor of Neanderthals, including a change driving faster cell growth, and report evidence of more muscle mass in modern humans who inherited the gene encoding the Neanderthal growth hormone receptor through admixture. Zhang et al. (2026) present a new method for identification of evidence of archaic ancestry in modern human genomes, and report evidence of an introgression from an unknown archaic lineage into the ancestors of modern humans before their migration out of Africa. Evidence of effectiveness of the imputation in detection of Neanderthal and Denisovan ancestry in low-coverage ancient genomes is presented by Capodiferro et al. (2026) . Rao et al.
Sources: en.wikipedia.org
The approved formulation is given by subcutaneous injection and is used on an as-needed basis rather than on a fixed daily schedule. An intranasal version was studied earlier but did not reach the same stage of development. Route of delivery strongly affects how quickly the peptide appears in circulation.
It means the product is taken shortly before anticipated activity instead of every day. This pattern reduces total exposure and shapes how safety monitoring is planned. It also means effects are expected to be temporary rather than cumulative.
Desire is assessed through validated self-report questionnaires, sometimes paired with event counts and a distress scale. These instruments capture subjective experience, so results depend on how participants interpret the questions. No laboratory marker currently substitutes for such reporting.
Reported activity is highest at MC4R, with lower potency at MC1R and MC3R. The MC4R interaction is generally treated as the most relevant to its central effects. Selectivity is not absolute, and activity across the family is dose-dependent.